Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410738 | 0.71 | — | — | |
| SCHEMBL17138262 | 0.69 | DPP4 (0.31) | — | |
| SCHEMBL17144498 | 0.66 | EPHX1 (0.35) | — | |
| SCHEMBL15667738 | 0.66 | CTSS (0.33) | ALDH1A1 | |
| SCHEMBL18896270 | 0.63 | SHBG (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4970041 | 0.63 | MMP2 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4969967 | 0.63 | GAA (0.41) | — | |
| Hydrochloric Acid SCHEMBL31185249 | 0.62 | TUBB1 (0.30) | — | |
| SCHEMBL5679173 | 0.62 | MMP2 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5053987 | 0.62 | MMP2 (0.39) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | ALDH1A1 4096/4885SMN1; SMN2 3512/4885 |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | ALDH1A1 4096/4885SMN1; SMN2 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.